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Abstract
IMPORTANCE Large studies investigating long-term outcomes of patients with bilateral
pheochromocytomas treated with either total or cortical-sparing adrenalectomies are needed to
inform clinical management.
OBJECTIVE To determine the association of total vs cortical-sparing adrenalectomywith
pheochromocytoma-specific mortality, the burden of primary adrenal insufficiency after bilateral
adrenalectomy, and the risk of pheochromocytoma recurrence.
DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from amulticenter
consortium-based registry for 625 patients treated for bilateral pheochromocytomas between 1950
and 2018. Data were analyzed from September 1, 2018, to June 1, 2019.
EXPOSURES Total or cortical-sparing adrenalectomy.
MAINOUTCOMESANDMEASURES Primary adrenal insufficiency, recurrent pheochromocytoma,
andmortality.
RESULTS Of 625 patients (300 [48%] female) with a median (interquartile range [IQR]) age of 30
(22-40) years at diagnosis, 401 (64%) were diagnosed with synchronous bilateral
pheochromocytomas and 224 (36%) were diagnosed with metachronous pheochromocytomas
(median [IQR] interval to second adrenalectomy, 6 [1-13] years). In 505 of 526 tested patients (96%),
germlinemutationswere detected in the genes RET (282 patients [54%]), VHL (184 patients [35%]),
and other genes (39 patients [7%]). Of 849 adrenalectomies performed in 625 patients, 324 (52%)
were planned as cortical sparing andwere successful in 248 of 324 patients (76.5%). Primary adrenal
insufficiency occurred in all patients treated with total adrenalectomy but only in 23.5% of patients
treated with attempted cortical-sparing adrenalectomy. A third of patients with adrenal insufficiency
developed complications, such as adrenal crisis or iatrogenic Cushing syndrome. Of 377 patients who
became steroid dependent, 67 (18%) developed at least 1 adrenal crisis and 50 (13%) developed
iatrogenic Cushing syndrome during median (IQR) follow-up of 8 (3-25) years. Two patients
developed recurrent pheochromocytoma in the adrenal bed despite total adrenalectomy. In
(continued)
Key Points
Question Is cortical-sparing
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with bilateral pheochromocytomas
compared with total adrenalectomy?
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pheochromocytomas, most had
hereditary syndromes, but 36% initially
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Abstract (continued)
contrast, 33 patients (13%) treated with successful cortical-sparing adrenalectomy developed
another pheochromocytomawithin the remnant adrenal after a median (IQR) of 8 (4-13) years, all of
which were successfully treated with another surgery. Cortical-sparing surgery was not associated
with survival. Overall survival was associatedwith comorbidities unrelated to pheochromocytoma: of
63 patients who died, only 3 (5%) died of metastatic pheochromocytoma.
CONCLUSIONS ANDRELEVANCE Patients undergoing cortical-sparing adrenalectomy did not
demonstrate decreased survival, despite development of recurrent pheochromocytoma in 13%.
Cortical-sparing adrenalectomy should be considered in all patients with hereditary
pheochromocytoma.
JAMA Network Open. 2019;2(8):e198898. doi:10.1001/jamanetworkopen.2019.8898
Introduction
Pheochromocytomas are tumors that store and release catecholamines in excess, leading to
episodes of hypertension, profuse sweating, headaches, panic attacks, arrhythmia, stroke, and
death.1 According to theWorld Health Organization classification, the term pheochromocytoma is
reserved for adrenal location, whereas similar tumors outside the adrenals are named
paragangliomas.2 Bilateral pheochromocytomasmay present either synchronously or
metachronously. Bilateral pheochromocytomas are often heritable and have been shown to occur
mainly in patients withmultiple endocrine neoplasia type 2 (MEN 2) caused by germlinemutations of
the RET (rearranged during transfection) proto-oncogene, von Hippel-Lindau disease (VHL; VHL
gene) and the paragangliomas syndromes types 1 and 4 caused bymutations in the succinate
dehydrogenase (SDH) subunit D (SDHD) and B (SDHB) genes, respectively.3-5 Other less common
genes associated with pheochromocytoma include neurofibromatosis type 1 (NF1), SDHA, SDHC,
SDH assembly factor 2 (SDHAF2), transmembrane protein 127 (TMEM127),MYC-associated factor X
(MAX), and several recently reported genes, such as SLC25A11, FH, andMDH2.6-12
The standard treatment of pheochromocytoma is resection.13 However, in bilateral
pheochromocytomas, the removal of the tumor only vs the entire adrenal gland remains an open
question. The 2014 Endocrine Society management guidelines14 recommend cortical-sparing
adrenalectomy for bilateral and hereditary pheochromocytoma based on low grade of evidence.
Although following guidelines in specialized centers demonstrated favorable short-term outcomes,
uncertainty remains because of the greater than 10% risk ofmetastatic pheochromocytomas and the
potential of developing new ipsilateral pheochromocytomas.15,16
We sought to compare outcomes of total and cortical-sparing adrenalectomy in a large cohort
of patients with bilateral pheochromocytoma with objectives to (1) describe the reasons for
recommending total vs cortical-sparing adrenalectomy, (2) determine the burden of steroid
dependency, (3) determine the risk of pheochromocytoma recurrence after cortical-sparing
adrenalectomy, and (4) determine the outcome of total vs cortical-sparing adrenalectomy on
pheochromocytoma-specific mortality.
Methods
We established the European-American-Asian-Bilateral-Pheochromocytoma-Registry, which
included patients who underwent surgery for bilateral pheochromocytomas either simultaneously or
by subsequent procedures. The institutional review boards for human subjects’ protection or ethical
committees of all participating centers approved this study. Patients provided written informed
consent or consent waiver, according to the local protocols. In The Netherlands, data were collected
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anonymously, and no further ethical approval was required. This study followed the Strengthening
the Reporting ofObservational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.
Data were analyzed from September 1, 2018, to June 1, 2019.
The registry was initiated on May 1, 2018, and was based on our International-MEN-2-
Pheochromocytoma-Registry and our prospectively accrued
European-American-Asian-Pheochromocytoma-Paraganglioma-Registry.7,17 It was open to any
additional center and any patients with bilateral pheochromocytoma, which resulted in the number
of registrants nearly doubling. The project was performed as an international, multicenter cohort
study with retrospective examination of data collected from a prospective clinical protocol on which
all centers collaborated. All centers recontacted the patients; thus, 57% of the registrants’
information was updated in 2018 (eTable 1 in the Supplement).
We systematically registered demographic, clinical, andmolecular genetic data that included
the year of operations on adrenals and the size, location, and number of tumors. We also collected
data on surgical treatment. We considered cortical-sparing adrenalectomy unsuccessful when the
patient became steroid dependent.
The diagnosis of surgically induced hypocortisolism was based on the cortisol measurements
(with or without cosyntropin stimulation test) after surgery. In steroid-dependent patients, we
registered the doses of glucocorticoid andmineralocorticoid replacement therapy. We verified
whether there were episodes of undertreatment (eg, weakness, skin pigmentation, anorexia,
vomiting, nausea, orthostatic hypotension, and/or hypoglycemia). We registered the number of
adrenal crises (defined as acute hypotension, fatigue, progressive weakness, and abdominal
discomfort necessitating high doses of glucocorticoids), and we searched for events that incited the
crises. We registered signs of glucocorticoid overtreatment (iatrogenic Cushing syndrome) as
new-onset diabetes, obesity, weakness or fatigability, osteoporosis, and fractures. In all patients, we
registered the development of ipsilateral recurrence and whether removal resulted in steroid
dependency as well as occurrence of malignancy. If an individual was deceased, the cause of death
was retrieved.
All patients were offered genetic counseling andmolecular genetic analyses for the
pheochromocytoma susceptibility genes, including RET, VHL, MAX, SDHA, SDHB, SDHC, SDHD,
SDHAF2, TMEM127, and NF1. We performed Sanger sequencing for all exons of these genes and
searched for large deletions or rearrangements bymultiplex ligation-dependent probe amplification
in VHL,MAX, SDHA, SDHB, SDHC, SDHD, SDHAF2, and TMEM127. For neurofibromatosis type 1 (NF-1),
presence of skin neuromas was regarded as equivalent to mutation positivity.18 Registrants were
classified asmutation negative if they had no pathogenic DNA variant in these 9 genes and no clinical
evidence for NF-1.19 The results of molecular genetic analysis and the protocols of molecular genetic
screening were evaluated by one of us (F.S.) (eTable 2 in the Supplement).
Statistical Analysis
Continuous data are presented as median and interquartile range (IQR), while categorical variables
are presented as absolute and relative frequencies. We performed statistical comparisons of
quantitative data with student t tests or analysis of variances. For statistical comparisons of
dichotomous data, we used the χ2 test. All statistical tests were 2-sided with P < .05 considered
statistically significant.
Results
The European-American-Asian-Bilateral-Pheochromocytoma-Registry, a collaboration of 45 centers
from 19 countries, included a total of 625 patients (300 [48%] female) as of December 31, 2018. The
median (IQR) age at diagnosis with pheochromocytoma was 30 (22-40) years (Table 1). Initial
diagnosis of pheochromocytoma occurred between 1950 and 2018. Of 625 patients, 401 (64%)
were diagnosed with synchronous bilateral pheochromocytomas and 224 (36%) with metachronous
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pheochromocytomas, with the contralateral pheochromocytoma diagnosed after a median (IQR)
interval of 6 (1-13) years.
Information on the size of pheochromocytomawas available based on computed tomography
scans and/or magnetic resonance imaging for 919 adrenal glands, which demonstrated single small
pheochromocytoma with a mean diameter of up to 2.5 cm in 330 glands (36%), medium-sized
pheochromocytoma of 2.6 to 5.0 cm in 364 glands (40%), large pheochromocytoma of greater than
5.0 cm in 157 glands (17%), andmultiple pheochromocytomas in 68 glands (7%). In addition to
adrenal pheochromocytomas, 66 patients had paragangliomas, which were not included in further
analyses.
Of 849 adrenalectomies performed in 625 patients, 324 (52%) were planned as cortical sparing
and were successful in 248 of 324 patients (76.5%). Steroid dependency developed in 377 patients,
301 of whom had been treated with total adrenalectomy and 76 of whom had undergone
unsuccessful cortical-sparing adrenalectomy (Figure). Synchronous bilateral adrenalectomywas
performed in 401 patients (64%), whereas 224 patients (36%) had a second adrenalectomy for a
contralateral pheochromocytoma at a median (IQR) of 8 (4-13) years after the first surgery. Of 401
patients undergoing synchronous bilateral adrenalectomies, 193 (48%) were treated with cortical-
sparing adrenalectomy. In contrast, of 224 patients who underwent metachronous bilateral
adrenalectomy, 131 (58%) had a cortical-sparing operation, although only 62 (28%) had cortical-
sparing adrenalectomy at first presentation. Primary adrenal insufficiency occurred in all patients
treated with total adrenalectomy but only in 23.5% of patients treated with attempted cortical-
sparing adrenalectomy. A third of patients with adrenal insufficiency developed complications, such
as adrenal crisis or iatrogenic Cushing syndrome.
Of 849 adrenalectomies, 395 (47%) were endoscopic operations performed in 322 patients;
44%were performed laparoscopically through frontal approach, 46% through retroperitoneal
posterior approach, and 10% through retroperitoneal lateral approach.
Patients treated with cortical-sparing adrenalectomy presented with smaller size of
pheochromocytoma (median size, 30mm; 95%CI, 30.14-34.37mm) comparedwith patients treated
with total adrenalectomy (median size, 35 mm; 95% CI, 34.54-40.05mm) (P < .001). Success of
Table 1. Demographic and Genetic Data of All Registrants
Characteristic
No. (%)
P Value
Total
(N = 625)
Steroid Dependent
(n = 377)
Steroid Independent
(n = 248)
General features
Female 301 (48.2) 195 (51.7) 106 (42.7) .03
Age at diagnosis, y <.001
Median (IQR) 30 (22-41) 31 (25-42) 27 (18-40)
95% CI 31.89-34.55 27.99-31.83
Gene mutated
RET 282 (53.6) 207 (69.9) 75 (32.6) <.001
VHL 184 (35.0) 74 (25.0) 110 (47.8) <.001
NF1 17 (3.2) 9 (3.0) 8 (3.5) .60
MAX 9 (1.7) 3 (1.0) 6 (2.6) .09
SDHD 7 (1.4) 0 7 (3.0) .001
TMEM127 5 (0.9) 2 (0.7) 3 (1.4) .40
SDHB 1 (0.2) 1 (0.4) 0 .40
No mutation found 21 (4.0) 0 21 (9.1) <.001
Genetic syndromes by
clinical data
Total 469 (75.2) 316 (83.8) 153 (61.6) <.001
Other syndromic tumor
in proband
348 (55.4) 250 (65.7) 98 (39.5) <.001
Family history of a
syndrome
290 (46.4) 188 (49.8) 102 (41.1) .06
Abbreviation: IQR, interquartile range.
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cortical-sparing adrenalectomywas not associated with size (successful: median size, 30mm; 95%
CI, 29.55-34.27 mm vs not successful: median size, 31 mm; 95% CI, 33.96-38.72mm; P = .60).
Patients were more likely to be treated with cortical-sparing adrenalectomy since 2010 (135 of
225 [60%] vs 189 of 400 [47%]; P = .002). Moreover, cortical-sparing adrenalectomy was more
likely to be successful in 2010 or later compared with before 2010 (156 of 189 [83%] vs 92 of 135
[68%]; P = .003). Certain centers were more likely to proceed with cortical-sparing adrenalectomy;
178 of 324 cortical-sparing adrenalectomies (55%) were performed in Germany, as opposed to only
146 of 324 (45%) in other centers (difference, 10%; 95% CI, 7%-14%; P < .001).
Genetics
Mutation analysis was performed for all susceptibility genes (RET, VHL, MAX, SDHA, SDHB, SDHC,
SDHD, SDHAF2, and TMEM127) in 526 patients (84%) and germline mutations were detected in 505
patients (96%).Mutations of RETwere present in 282 patients, VHL in 184,NF1 in 17,MAX in 9, SDHD
in 7, TMEM127 in 5, and SDHB in 1 (Table 1). In contrast, clinical evidence of heritability by patient
history and family history was positive in only 469 of 625 patients (75%). A total of 576 of 625
patients (92%) carried at least 1 clinical hallmark of heredity, such as any neoplasia that is a
component of pheochromocytoma syndromes. These included 48 patients with clinical evidence of
MEN 2 (of 330 total patients with MEN 2), 7 patients with VHL-associated hemangioblastomas (of
191 total patients with VHL), and 14 patients with relatives who had pheochromocytomas.
Outcomes
Follow-up data were available for 558 patients for a median (IQR) of 8 (3-25) years. Of 377 patients
who became steroid dependent, 301 (80%) underwent complete bilateral adrenalectomy and 76
(20%) had an attempted but unsuccessful cortical-sparing surgery (Figure and Table 2). Of the 248
steroid-independent patients, all had successful cortical-sparing operations (Figure). Patients with
MEN 2 were more likely to present with synchronous bilateral pheochromocytoma compared with
patients with VHL (222 of 330 [67%] vs 108 of 191 [57%]; difference, 10%; 95% CI, 2%-19%; P = .01)
Figure. Schema for Bilateral Pheochromocytoma Registrants, Their Operations, and Steroid-Dependent vs Steroid-Independent Outcomes
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MEN 2 indicates patients with medullary thyroid carcinoma plus pheochromocytoma
and/or patients with a RETmutation; VHL, pheochromocytomawith hemangioblastoma
of eyes or central nervous system and/or patients with a VHLmutation; other, patients
with a mutation in one of the genes SDHD, SDHB,MAX, or TMEM127 or signs of
neurofibromatosis type 1 or clinically familial pheochromocytomas.
JAMANetworkOpen | Diabetes and Endocrinology Total vs Cortical-Sparing Adrenalectomy for Bilateral Pheochromocytomas
JAMA Network Open. 2019;2(8):e198898. doi:10.1001/jamanetworkopen.2019.8898 (Reprinted) August 9, 2019 5/13
Downloaded From: https://jamanetwork.com/ by a Helsinki Univeristy Library User  on 10/28/2019
and weremore frequently treated with total adrenalectomy (198 of 330 [60%] vs 62 of 191 [32%];
difference, 28%; 95% CI, 19%-36%; P < .001). When cortical-sparing adrenalectomywas attempted,
it was less likely to be successful in patients withMEN 2 comparedwith patients with VHL (82 of 132
[62%] vs 112 of 129 [87%]; difference, 25%; 95% CI, 14%-34%; P < .001). Metastatic
pheochromocytoma occurred in 4 of 191 patients with VHL (2%), as opposed to 1 of 330 patients
with MEN 2 (0.3%) (difference, 2%; 95% CI, 0%-5%; P = .06). Patients with VHLwere at higher risk
for development of recurrent ipsilateral pheochromocytoma compared with patients with MEN 2
overall (23 of 191 [12%] vs 8 of 330 [2%]; difference, 10%; 95% CI, 5%-15%; P < .001), as well as
among all patients undergoing cortical-sparing adrenalectomy only (21 of 129 [16%] vs 8 of 132 [6%];
difference, 10%; 95% CI, 3%-18%; P = .01).
Recurrent ipsilateral pheochromocytoma developed in 35 of 625 patients (5.6%). Ipsilateral
recurrence after successful cortical-sparing adrenalectomy occurred in 33 of 248 patients (13%) after
amedian (IQR) of 8 (4-17) years, as well as 2 of 301 patients aftermedians of 9 and 25 years after total
adrenalectomy (difference, 13%; 95% CI, 9%-17%; P < .001) (Figure). Of the 33 patients who
developed ipsilateral recurrence after successful cortical-sparing adrenalectomy, 10 (30%) became
Table 2. OutcomeData for All Registrants
Outcome
No./Total No. (%)
P Value
Total
(n = 625)
Steroid
Dependent
(n = 377)
Steroid
Independent
(n = 248)
Follow-up, median (IQR), y 8 (3-25) 10 (4-22) 7 (3-13) <.001
Relapse in ipsilateral adrenal 35/625 (5.6) 2/377 (0.5) 33/248 (13.3) <.001
Adrenal crises at least once 67/625 (10.7) 67/377 (17.7) NA NA
No. of adrenal crises 177/625 (28.3) 177/377 (46.9) NA NA
No. of patients with metastases of any
primary
47/625 (7.5) 37/377 (9.8) 10/248 (4.0) .001
No. of deaths 63/625 (10.1) 47/377 (12.4) 16/248 (6.4) <.001
Symptoms of steroid overdosing 50/625 (8.0) 50/377 (13.2) NA NA
Causes of adrenal crises
Infection 45/67 (67.2) 45/67 (67.2) NA NA
Stress 14/67 (20.9) 14/67 (20.9) NA NA
Trauma 2/67 (3.0) 2/67 (3.0) NA NA
Withdrawal or noncompliance 6/67 (9.0) 6/67 (9.0) NA NA
Metastatic tumors in living patients
Pheochromocytoma or paraganglioma 8/37 (21.6) 5/29 (17.2) 3/8 (37.5) .90
Multiple endocrine neoplasia type 2
with medullary thyroid carcinoma
18/37 (48.7) 18/29 (62.1) 0/8 .001
VHL with renal cell carcinoma 2/37 (5.4) 2/29 (6.9) 0/8 .50
VHL with pancreatic neuroendocrine
tumor
7/37 (18.9) 3/29 (10.3) 4/8 (50) .40
VHL with other 0/37 0/29 0/8 >.99
Nonsyndromic cancer 2/37 (5.4) 1/29 (3.5) 1/8 (12.5) .80
Causes of deaths
Pheochromocytoma or paraganglioma 3/63 (4.8) 2/47 (4.3) 1/16 (6.25) >.99
Adrenal crises 2/63 (3.2) 2/47 (4.3) NA NA
Multiple endocrine neoplasia type 2
with medullary thyroid carcinoma
31/63 (49.2) 25/47 (53.2) 6/16 (37.5) .001
VHL with renal cell carcinoma 1/63 (1.6) 1/47 (2.1) 0/16 >.99
VHL with pancreatic neuroendocrine
tumor
3/63 (4.8) 1/47 (2.1) 2/16 (12.5) .50
VHL with other 3/63 (4.8) 2/47 (4.3) 1/16 (6.3) >.99
Nonsyndromic cancer 8/63 (12.7) 6/47 (12.8) 2/16 (12.5) >.99
Other cause or unknown 12/63 (19.1) 8/47 (17.0) 4/16 (25.0) >.99
Abbreviations: IQR, interquartile range; NA, not
applicable; VHL, von Hippel-Lindau disease.
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steroid dependent after a second surgery. None of the patients treated with unsuccessful cortical-
sparing adrenalectomy experienced recurrence (0 of 76 [0%] vs 33 of 248 [13%]; difference, 13%;
95% CI, 7%-18%; P < .001).
Metastatic pheochromocytoma developed in 8 of 625 patients (1.3%), including 1 patient
treatedwith total adrenalectomy and 7 patients treatedwith cortical-sparing adrenalectomy (1 of 301
[0.3%] vs 7 of 324 [2%]; difference, 2%; 95% CI, 0%-4%; P = .07). Metastatic pheochromocytoma
wasmore common in patients with metachronous pheochromocytomas (6 of 224 [2.7%] vs 2 of 401
[0.5%]; difference, 2%; 95% CI, 0.2%-5%; P = .03). One of the 8 patients with metastatic
pheochromocytomawas diagnosed prior to adrenalectomy, and in another 3 patients, the origin of
metastases was likely a coexisting paraganglioma. Of the 8 patients with metastatic
pheochromocytoma, 4 patients had germline mutation in VHL, 1 inMAX, and 1 in RET.
An additional 269 patients developedmalignant neoplasms other than pheochromocytoma.
These includedmedullary thyroid carcinoma (MTC) in 223 of 330 (68%) with MEN 2. Renal cell
carcinoma and pancreatic neuroendocrine tumors were seen in 37 of 191 patients (19%) with VHL.
Nine further patients had malignant neoplasms not associated with MEN 2, VHL, or
pheochromocytoma syndromes.
Complications of Steroid Replacement
Patients became steroid dependent at a median (IQR) age of 34 (27-43) years; 41 of 377 patients
(11%) were younger than 20 years. They were treated with a median (IQR) daily dose of
hydrocortisone of 30 (20-30) mg; in addition, 294 patients (78%) also required fludrocortisone at a
median (IQR) daily dose of 0.05 (0.05-0.1) mg. Median (IQR) duration of steroid use was 13 (4-20)
years.
Of 377 steroid-dependent patients, 67 (18%) developed at least 1 adrenal crisis; 22 patients
(6%) had 2 or more adrenal crises (total, 177 events). Reasons for adrenal crisis development were
infections (68%), stress (20%), noncompliance or medication errors (9%), and trauma (3%).
During follow-up, 50 patients (13%) developed symptoms consistent with steroid
overreplacement. Of these 50, 21 (42%) were treated with hydrocortisone doses of more than 25mg
daily, whereas 29 patients (58%) were treated with physiological hydrocortisone replacement.
Overall Survival
Overall survival was associated with comorbidities unrelated to pheochromocytoma: among 63
patients who died, only 3 (5%) died of metastatic pheochromocytoma.
Cortical-sparing surgery was not associated with pheochromocytoma-specific survival. During
median (IQR) follow-up of 8 (4-17) years, overall survival of steroid-dependent patients was
significantly lower compared with steroid-independent patients (85% vs 99%; difference, 14%; 95%
CI, 11%-18%; P = .01); however, most of the difference was due to higher rates of MEN 2 (and
metastatic MTC) in steroid-dependent patients. Of the 47 steroid-dependent patients who died, 25
(53%) died of metastatic MTC, 2 (4%) of metastatic pheochromocytoma, 2 (4%) of adrenal crises, 4
(8%) of VHL complications, and 14 (30%) ofmorbidity unrelated to pheochromocytoma syndromes.
In contrast, of the 16 steroid-independent patients who died, 1 (6%) hadmetastatic
pheochromocytoma, 6 (38%) hadmetastatic MTC, 3 (19%) had VHL-related complications, and 6
(38%) died of unrelated causes.
Discussion
Patients with bilateral pheochromocytomas are frequently treated with total bilateral
adrenalectomy. While cortical-sparing adrenalectomywas introduced in practice in 1999, it is still a
relatively underused procedure.20-23 A recent meta-analysis16 reported that cortical-sparing
adrenalectomy can reduce the need for steroid replacement therapy and carries a low risk for
recurrence, based onmainly retrospective studies of small sample size. Overall, the evidence for use
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of cortical-sparing adrenalectomy in patients with bilateral pheochromocytomas is minimal, leading
to only aweak recommendation in the recent guidelines onmanagement of pheochromocytoma.14,16
In this article, we present data on outcomes of treatment in patients with bilateral
pheochromocytomas based on a retrospective-prospective series of 625 patients enrolled in 19
countries followed up for amedian of 8 years. A large number of patients undergoing cortical-sparing
adrenalectomy allowed us to perform subgroup analyses for both common and rare outcomes, such
as risk of metastatic or recurrent disease, risk of adrenal insufficiency, and complications of steroid
replacement therapy.
In our cohort of patients treated with cortical-sparing adrenalectomy, recurrent
pheochromocytoma in the spared ipsilateral adrenal gland occurred in 13% of patients, mostly in
patients with VHL andMEN 2, similar to the reported 8% to 10% in other studies.16,24 Recurrence
occurred as little as 1 year and as much as 27 years after cortical-sparing adrenalectomy. As several
patients were diagnosed with early recurrence, it is likely that this was a case of missed second
pheochromocytoma rather than a true recurrence. In all these patients, recurrent tumors were
successfully removed, and most patients remained steroid independent, thus avoiding or delaying
the onset of adrenal insufficiency.
As expected, all patients undergoing bilateral total adrenalectomy became steroid dependent.
However, we also found that 23% of patients with cortical-sparing adrenalectomy developed adrenal
insufficiency, requiring lifelong steroid replacement (Figure). The reasons for adrenal insufficiency
developing in patients with spared adrenals could be insufficient blood supply to the remaining
adrenal gland or inadequate remaining cortical tissue. In steroid-dependent patients, complications
of either disease or treatment were frequent, as 18% of patients developed at least 1 adrenal crisis
during follow-up, and manifestations of iatrogenic Cushing syndrome (overreplacement with
glucocorticoids) occurred in 13%. As patients were frequently treated with hydrocortisone doses
greater than 20 to 25mg per day, it is possible that the high prevalence of iatrogenic Cushing
syndrome in our cohort was also due to a higher daily steroid replacement standard in the past.
It is important to note that the patients undergoing cortical-sparing adrenalectomy had slightly
smaller pheochromocytomas in our study. Indeed, total adrenalectomy has been suggested for large
pheochromocytomas.1,25
As expected, most patients with bilateral pheochromocytoma had a predisposing genetic
mutation, as demonstrated in 96% of patients in our cohort with available testing. Molecular
genetics can dramatically improve preoperative characterization of patients as having heritable vs
sporadic pheochromocytoma.26 The most frequent mutations in our cohort involve RET leading to
MEN 2 and VHL leading to VHL disease. Although personal and family histories are important in
diagnosing heritable pheochromocytoma, patients with an underlying germline mutation often
present without hallmark clinical features suggestive of a particular hereditary syndrome.4,7,9,27
Availability of DNA sequencing provides a powerful diagnostic tool to identify suchmutations in
patients with apparently sporadic pheochromocytoma. This is poignantly illustrated by the fact that
36% of our cohort initially presenting with unilateral pheochromocytoma subsequently developed
contralateral disease. In these patients, molecular genetic results could have changed initial
management,17,28,29 leading to the decision to proceed with a cortical-sparing surgery in patients at
high likelihood of future contralateral disease. Moreover, an individualized monitoring approach to
include workup for nonpheochromocytoma manifestations of a specific syndrome could have been
instituted at an earlier time.
We found that steroid-dependent patients demonstrated a higher mortality when compared
with patients with preserved adrenal function; notably, this increased mortality was mainly
attributed tometastatic MTC in patients with MEN 2, who were overrepresented among patients
with primary adrenal insufficiency. However, it is important to note that in 2 patients, adrenal crisis
was themain cause of death.
Patients with pheochromocytoma, and especially hereditary pheochromocytoma, benefit from
an expert multidisciplinary team including an adrenal endocrinologist, surgeon, oncologist, and
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geneticist. Adrenal surgical expertise is not widely available, with less than one-third of all surgeons
performing more than 4 adrenalectomies per year.30 Cortical-sparing adrenalectomy necessitates
even higher surgical expertise and should be performed by a high-volume adrenal surgeon.
Cortical-sparing adrenalectomymay be performed during open or minimally invasive
adrenalectomy. While there is wide variation regarding the technical aspects of this complex
procedure, certain suggestions can be reasonably made. Prior to mobilization and devascularization
of the pheochromocytoma, intraoperative ultrasonography should be performed to define the
anatomy of the pheochromocytoma relative to the remaining normal adrenal gland and the adrenal
vein. This will optimize operative planning and allow the surgeon to devascularize only the portion of
adrenal that is to be resected. Furthermore, ultrasonography will help exclude additional ipsilateral
pheochromocytomas, which may be small and unexpected based on preoperative imaging.
Extracapsular dissection andmobilization of the pheochromocytoma should be performed, ensuring
not to rupture the capsule, which can result in recurrence. A remnant one-third the size of a normal
adrenal gland is adequate for appropriate synthetic function.23,31,32
Limitations
This study had several limitations. The retrospective portion of the study did not allow for a uniform
data collection for certain variables; however, this allowed for longitudinal follow-up and a large
sample size otherwise impossible in a purely prospective study of this rare disease. Variability in local
protocols and/or local surgical expertise likely influenced the choice of therapy. The surgical approach
was decided by the surgeon based onmultiple factors, including tumor size and the ability to secure
vascular supply to the remaining adrenal cortex. Given the extensive period for patient enrollment,
certain approaches changed over the years, including choice of surgical procedures as well as
glucocorticoid replacement therapy.
Conclusions
This study found that undergoing cortical-sparing adrenalectomy for bilateral pheochromocytomas
was not associated with decreased survival, suggesting that it should be considered in patients with
hereditary pheochromocytoma. Based on our findings, we suggest consideration of several factors
when selecting an appropriate surgical procedure for a patient with pheochromocytoma. Cortical-
sparing adrenalectomy should be considered in patients with (1) bilateral pheochromocytomas, (2)
tumor size less than 5 cm, or (3) high likelihood of a predisposing mutation leading to high risk of
metachronous pheochromocytoma in the future. Our study suggests that cortical-sparing surgery for
pheochromocytoma is appropriate and safe in the right setting. All patients with
pheochromocytomas, even when presenting with apparently sporadic, unilateral disease, should be
offered genetic analysis preoperatively to ensure gene-informed surgical andmedical management.
Referral to highly specialized adrenal centers for multidisciplinary assessment and treatment should
be considered, especially in patients with hereditary pheochromocytoma syndromes.
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